what is glp-1 drugs How medications are transforming diabetes and weight loss treatment GLP-1 Agonists: Using Semaglutide, Tirzepatide,

PIONEER 2 PIONEER 2 was a 52-week, randomized, open-label trial enrolling 821 patients with T2DM

The main differences across comparison categories are: Receptor Targets: advantage goes to Retatrutide

Diabetic kidney disease: a report From an ADA Consensus Conference

A report of nine incidences of progressive vision loss among people using semaglutide or tirzepatide, the study adds to a growing body of work examining the trend, but study investigators point out there was no way to link the use of these new agents directly to ophthalmic conditions reported

A synthetic version was created in the years after, but it took until 2005 for this GLP-1 agonist to become an FDA-approved treatment for type 2 diabetes